Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-therapy for Acute Schizophrenic
Study identifier:D1443L00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 24-week, Multi-Centre, Open-label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) with Daily Dose 600mg-750mg as Mono-therapy in the Treatment of Acute Schizophrenic Patients
Medical condition
schizophrenia
Phase
Phase 4
Healthy volunteers
No
Study drug
Quetiapine Fumarate (Seroquel)
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
18 Years - 60 Years
Date
Study Start Date: 01 Dec 2006
Primary Completion Date: 01 Sept 2007
Study Completion Date: 01 Sept 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Jon Zhu
AstraZeneca
